Pharmaceuticals
I-Mab Announces Upcoming Participation at September Conferences
ROCKVILLE, Md. and SHANGHAI, Sept. 5, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), is a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies an...
2023-09-05 20:00
1419
GCCL to be the first in the industry sector to adopt Lab Information Management System (LIMS)
* The first clinical trial sample analysis provider to adopt LIMS * To provide enhanced quality of pharmacokinetic, pharmacodynamic, and immunogenicity data from bioanalytic testing YONGIN, South Korea, Sept. 4, 2023 /PRNewswire/ -- GCCL, a Korean clinical trial sample analysis company, annou...
2023-09-05 09:57
1345
ABM Therapeutics Announces First Patient Dosed in Phase I Study of ABM-1310 in patients with BRAF V600 in Relapsed and Drug Resistant Primary Malignant Brain Tumors
SAN DIEGO, Calif. and SHANGHAI, Sept. 1, 2023 /PRNewswire/ -- ABM Therapeutics, a clinical-stage biopharmaceutical company, today announced that the first patient has been successfully dosed in its multicenter Phase I study of ABM-1310 in patients with relapsed and drug resistant primary malignan...
2023-09-02 00:00
3177
Adicon Holdings Limited (9860.HK): Continuous growth in Core Operations, Consistent Profitability Enhancement
HANGZHOU, China, Sept. 1, 2023 /PRNewswire/ -- Adicon Holdings Limited (the "Company" or "Adicon"), one of the largest independent clinical laboratory (ICL) service providers listed on the Stock Exchange ofHong Kong (SEHK), has released its interim results for the first half of 2023. As a leading...
2023-09-01 21:30
5634
CANbridge Announces Interim Financial Results and Corporate Updates for the Six Months Ended June 30, 2023
BEIJING and CAMBRIDGE, Mass., Aug. 31, 2023 /PRNewswire/ -- CANbridge Pharmaceuticals, Inc. ("CANbridge," stock code 1228.HK), a global biopharmaceutical company, with a foundation inChina, committed to the research, development and commercialization of transformative therapies for rare diseases...
2023-08-31 15:15
3954
Tycoon Group Announces 2023 Interim Results
The Group's Revenue Hits New Heights Net profit for 1H2023 increased more than 2.8 times YoY Benefited from the Full Resumption of Normal Travel Revenue Continues to Generate Profit in Future Results Highlights * Since the full resumption of normal travel between Hong Kong, Macau and Mainland C...
2023-08-31 13:28
4044
LOTTE BIOLOGICS Holds 'ESG Declaration Ceremony'
* Announces Human Rights and Environmental Management Charter Alongside Annual Implementation Strategies within its Mid-to-Long-term ESG Roadmap * Strengthens Eco-friendly Policies, Including Greenhouse Gas Reduction Plans from the Initial Factory Design Stage SEOUL, South Korea, Aug. 30, 20...
2023-08-31 09:00
1763
GC Biopharma to organize "Donate Blood with Love", a healthy way of giving back to the community
With the participation of all affiliated group entities YONGIN, South Korea, Aug. 30, 2023 /PRNewswire/ --All executives and employees of GC Biopharma, a South Korean biopharmaceutical company, rolled up their sleeves to practice ESG and social value. On Aug. 30th, the company held the "Donate...
2023-08-30 16:05
1382
Asieris Obtained IND Approval from NMPA for APL-1401, a Drug for the Treatment of Moderately-to-Severely Active Ulcerative Colitis
SHANGHAI, Aug. 30, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that the National Medical Products Adm...
2023-08-30 14:19
1423
InxMed Receives Approval to Initiate Phase I Clinical Trial in China for OMTX705, a First-in-Class FAP-Targeting ADC
NANJING, China, Aug. 29, 2023 /PRNewswire/ -- InxMed, a clinical-stage biotechnology company dedicates on developing innovative therapies targeting drug resistance for hard-to-treat solid tumors，announced today the first-in-class ADC OMTX705 has obtained the IND (Investigational New Drug) approv...
2023-08-30 11:00
1820
Fosun Pharma Announces 2023 Interim Results: Continues to Promote Innovation Transformation and Optimizes Product Structure
SHANGHAI, Aug. 29, 2023 /PRNewswire/ -- On August 29, 2023, Shanghai Fosun Pharmaceutical Co., Ltd.* (Stock Code: 600196.SH; 02196.HK) announced its 2023 Interim Results for the first half of 2023. (the "Reporting Period"). During the Reporting Period, Fosun Pharma achieved revenue ofRMB21.395 bi...
2023-08-30 10:53
2772
Akeso Announced 2023 Interim Results: First Profit, Growing Sales of PD-1/CTLA-4 Bispecific Antibody and Priority Review of PD-1/VEGF
—During the reporting period, Akeso's revenue was RMB3,676.9 million, an increase of 2,154.4% from 2022H1; Akeso recorded a profit ofRMB2,489.5 million. —RMB2,915.2 million was recognized by Akeso as license fee income during the reporting period due to the receipt of an upfront payment equivalen...
2023-08-30 08:03
2265
Cerecin to Present New Infantile Spasms Data at the 35th International Epilepsy Congress, Dublin 2023
* Data from the pilot study in infantile spasms showed positive outcomes. * The results will be presented by Cerecin's Chief Medical Officer, Dr. Marc Cantillon on Sunday 2nd September at 2pm (GMT+1). * The Cerecin team will be accompanied by PharmaVentures, who will be supporting Cerecin's ...
2023-08-30 00:02
1221
Akeso Announced Completion of Patient Enrollment in Phase 3 Trial of Ivonescimab (PD-1/VEGF) versus Pembrolizumab in First-line PD-L1 Positive Advanced NSCLC
HONG KONG, Aug. 29, 2023 /PRNewswire/ -- Akeso Inc. ("Akeso", 9926. HK) announced completion of patient enrollment in a head-to-head study of ivonescimab (AK112, PD-1/VEGF bispecific antibody) compared with pembrolizumab as first-line treatment for patients with PD-L1 positive (PD-L1 TPS≥1%) loca...
2023-08-29 20:00
1352
ProfoundBio to Participate in the 21st Annual Morgan Stanley Conference
SEATTLE, Aug. 28, 2023 /PRNewswire/ -- ProfoundBio, a clinical-stage biotechnology company focused on the development of novel antibody-drug conjugate therapeutics for cancer, announced that management will be participating in one-on-one meetings at the Morgan Stanley 21st Annual Global Healthca...
2023-08-28 20:00
1258
Harbour BioMed Announces 2023 Interim Results
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Aug. 28, 2023 /PRNewswire/ -- Harbour BioMed ("HBM", or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology an...
2023-08-28 17:08
2446
Harbour BioMed Announces US IND Clearance of Its First ADC Program HBM9033 in Solid Tumors
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Aug. 28, 2023 /PRNewswire/ -- Harbour BioMed (the"Company", HKEX: 02142) announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application to commence clinical trials of its first antib...
2023-08-28 16:30
1483
Specialised Therapeutics acquires commercialisation rights to new oral MND therapy
.. ST to partner with Dutch biotech company Treeway BV .. First CNS therapy in ST therapeutic portfolio SINGAPORE, Aug. 27, 2023 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST) will partner withNetherlands based biotechnology company Treeway BV to...
2023-08-28 04:00
1629
First participant treated at the highest dose level in Clarity's theranostic prostate cancer trial
Highlights * First participant of cohort 3 in the theranostic SECuRE trial investigating 64Cu/67Cu SAR-bisPSMA in metastatic castrate-resistant prostate cancer (mCRPC) has been treated at the highest dose level of 12GBq. * Cohort 2 was recently completed in 3 participants who received therapy...
2023-08-25 20:58
2706
Akeso Announced that Ivonescimab Granted Priority Review of NDA by China NMPA
HONG KONG, Aug. 25, 2023 /PRNewswire/ -- Akeso Inc. ("Akeso", the "Company"; 9926.HK), a commercial-stage biopharmaceutical company focused on developing and commercializing first-in-class and best-in-class innovative medicines globally, announced today that the National Center for Drug Evaluatio...
2023-08-25 20:00
2240
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
8005
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7400